NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Monday that its first-quarter revenues declined 1 percent year over year as a decline in product revenues was offset by growth for its clinical lab services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.